"Authorized" Generics Reduce The Incentive For Patent Challenges, GPhA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
"Authorized" generics reduce the incentive for generic manufacturers to challenge questionable pharmaceutical patents, the Generic Pharmaceutical Association says
You may also be interested in...
GPhA Talking To CMS About Medicaid "Best Price" For "Authorized" Generics
Federal and state governments are losing "substantial dollars" because innovators are not including authorized generics in their best price calculations for brand drugs, GPhA CEO Jaeger says. The group is highlighting the "inconsistency" in how FDA and the Centers for Medicare & Medicaid Services treat authorized generics.
GPhA Talking To CMS About Medicaid "Best Price" For "Authorized" Generics
Federal and state governments are losing "substantial dollars" because innovators are not including authorized generics in their best price calculations for brand drugs, GPhA CEO Jaeger says. The group is highlighting the "inconsistency" in how FDA and the Centers for Medicare & Medicaid Services treat authorized generics.
"Authorized" Generics' Short-Term Benefits Outweighed By Drag On ANDAs, GPhA Says
Although authorized generics may stimulate competition, they undermine the incentive to submit generic drug applications, GPhA maintains. Association will "keep our options open" in determining "next steps."